-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A subset of patients with metastatic urothelial carcinoma (mUC) have a DNA repair deficient (DRD) phenotype that predicts benefit from platinum-based chemotherap.
DRD biomarker-positive mUC patients without cancer progression within 10 weeks of chemotherapy were randomized (1:1) to rucaparib (600 mg twice daily) or placebo and maintained until disease progres.
Of the 248 patients, 74 (28%) were positive for the DRD biomarker, 40 of whom were randomized into two groups (20 in each group.
In the safety population (n=39), treatment-related adverse reactions were more or less low-grad.
In conclusion, maintenance therapy with lucaparib after platinum-based chemotherapy can prolong the progression-free survival of patients with DRD biomarker-positive mUC, and it is well tolerate.
Original source:
Simon .